Shares of Vivus, Inc. ( VVUS - Get Report) declined by nearly 4% today after performing well the last couple of days based on a regulatory filing with the Securities and Exchange Commission. The filing indicated that an investment firm called Aspen Investment Fund LLC may make an offer to buy out the drug maker. However, there could be something fishy going on here, making this situation worth a second or third look by investors. This isn’t to say that something’s definitely wrong here. This entire situation could be entirely legitimate and Aspen might really be thinking about making an offer for Vivus, Inc. ( VVUS - Get Report). But there are causes for concern, with the big one being that the firm that said it might make an offer doesn’t appear to even be in U.S. regulatory databases.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Stocks
Jim Cramer Ponders a Tech Cold War and Zooms In on Target's Earnings Bullseye
Jim Cramer tackles the biggest headlines in the markets from the possibility of a tech cold war to Target's earnings to Qualcomm's antitrust ruling.
Novartis Is a Difficult Stock to Trade or Own - Suggested Risk Point
Let's review the charts and indicators this morning.
Target Hits a Bullseye With Latest Results and Shares Surge
Target is shining while the stars of many retail stocks dim.